Most medical device executives are reluctant to say anything that could in any way be construed as critical of the FDA or the agencies that determine reimbursement coverage decision. But not Robert "Skip" Cummins, president and CEO of neurostimulation pioneer Cyberonics. For the past two years, Cummins has been waging what has been a virtual one-man war with the FDA and major payers to make sure that psychiatrists and their patients have access to the only FDA-approved treatment for severe treatment resistant depression.
By David Cassak
Most medical device executives are reluctant to say anything that could in any way be construed as critical of the FDA or the agencies that determine reimbursement coverage decision. But...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.
Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.
